long intergenic non-protein coding RNA 1494Genealiases: []
Q-omics provides the consensus-scored LINC01494 profile across patient tissues and cancer cell-line models. LINC01494 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01494 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, LINC01494 RNA expression shows 12,877 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight COAD, HNSC, and LIHC as cancer lineages where LINC01494 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01494 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01494 survival associations across molecular data types. LINC01494 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01494 RNA expression–survival associations across cancer types. High LINC01494 expression shows unfavorable associations in COAD, THYM, ACC, UCEC and KICH, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01494 RNA expression.
This table summarizes LINC01494 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01494. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01494 shows higher tumor expression in HNSC, KIRC, LUSC, THCA, KIRP and LUAD. The HNSC box plot shows higher LINC01494 RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p < 0.001).
This table shows molecular features associated with LINC01494 in patient tissues and cancer cell lines. In patient samples, LINC01494 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
